Resource library

Presentations

Videos & animations

Research

Letters & Public comments

Media

Community Quest

Op-eds & blog posts

Community Outreach

Press releases

Presentations

Videos & Animations

Featured
Why is there a copay for breast cancer medicine?
Why is there a copay for breast cancer medicine?
Demand first dollar coverage for your medicines
Demand first dollar coverage for your medicines
Why is there a copay for cancer medicine?
Why is there a copay for cancer medicine?
Why is there a copay for insulin?
Why is there a copay for insulin?
Why is there a copay for asthma inhalers?
Why is there a copay for asthma inhalers?
The Massachusetts Paradox
The Massachusetts Paradox
A note of thanks to the FDA
A note of thanks to the FDA
Protect American Innovation
Protect American Innovation
The Investor’s Paradox
The Investor’s Paradox
Affordability & Innovation
Affordability & Innovation
Inventing new medicines is a long climb
Inventing new medicines is a long climb
What is Abbie Saving For?
What is Abbie Saving For?
The Value of Medicines
The Value of Medicines

Research

Featured
Fixing Insurance Gaps: A Roadmap for Improving ACA Health Plan Coverage
Fixing Insurance Gaps: A Roadmap for Improving ACA Health Plan Coverage
No More Freeriding on the Great American Drug Deal
No More Freeriding on the Great American Drug Deal
Valuing Healthcare Innovation
Valuing Healthcare Innovation
Foreign countries rely on flawed and outdated HTA or ”value assessment” methods to justify low prices for medicines
Foreign countries rely on flawed and outdated HTA or ”value assessment” methods to justify low prices for medicines
Price Controls Hinder Treatment Access in Medicare Part D
Price Controls Hinder Treatment Access in Medicare Part D
Consumers sound alarm: state price controls will limit access without lowering patient costs
Consumers sound alarm: state price controls will limit access without lowering patient costs
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold
NEW REPORT: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
NEW REPORT: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
Value in Health: It’s time to reconsider the three percent discount rate.
Value in Health: It’s time to reconsider the three percent discount rate.
Is the price right? Paying for value today to get more value tomorrow
Is the price right? Paying for value today to get more value tomorrow
When simpler isn’t better: a case for generalized cost-effectiveness analysis
When simpler isn’t better: a case for generalized cost-effectiveness analysis
Why the discount rate is exciting!
Why the discount rate is exciting!
The American Journal of Managed Care: Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
The American Journal of Managed Care: Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
Getting the math right when measuring the value of new medicines
Getting the math right when measuring the value of new medicines

Letters & Public Comments

Featured
Supporting the Call for Evidence-Based Policy and Public Health Security
Supporting the Call for Evidence-Based Policy and Public Health Security
A Letter to FDA Commissioner Marty Makary on the Importance of a Strong and Predictable FDA
A Letter to FDA Commissioner Marty Makary on the Importance of a Strong and Predictable FDA
Public Comment: Accelerate Safe and Effective Drug Access, PDUFA VIII
Public Comment: Accelerate Safe and Effective Drug Access, PDUFA VIII
Public Comment: Demand Equitable Contribution to Biomedical Innovation
Public Comment: Demand Equitable Contribution to Biomedical Innovation
A Letter to Senate HELP Committee Chairman Bill Cassidy on Preserving and Modernizing the FDA
A Letter to Senate HELP Committee Chairman Bill Cassidy on Preserving and Modernizing the FDA
Public Comment: End Unfair Trade Practices in Drug Pricing
Public Comment: End Unfair Trade Practices in Drug Pricing
Public Comment: Use tariff and market access tools to force OECD countries to pay their fair share for medical innovation
Public Comment: Use tariff and market access tools to force OECD countries to pay their fair share for medical innovation
Open letter to President Trump from biopharma innovators, investors, and patient advocates regarding proposed FDA budget and personnel cuts.
Open letter to President Trump from biopharma innovators, investors, and patient advocates regarding proposed FDA budget and personnel cuts.
Defending the NIH, the NSF, and the foundation of American science
Defending the NIH, the NSF, and the foundation of American science
Public Comment: Allow Medicare to cover anti-obesity medications (AOMs) and strengthen patient protection “guardrails” through better oversight of Medicare Advantage Part D (MAPD) plans.
Public Comment: Allow Medicare to cover anti-obesity medications (AOMs) and strengthen patient protection “guardrails” through better oversight of Medicare Advantage Part D (MAPD) plans.
Public Comment: Share savings from Medicare price setting with patients not plans
Public Comment: Share savings from Medicare price setting with patients not plans
NEW LETTER: Investors and executives urge the Congressional Budget Office to adopt changes to its modeling
NEW LETTER: Investors and executives urge the Congressional Budget Office to adopt changes to its modeling
Sign-on letter: Why Fixing the IRA Matters to all of us
Sign-on letter: Why Fixing the IRA Matters to all of us
Public Comment: Protect patients when implementing the price setting provisions of the Inflation Reduction Act
Public Comment: Protect patients when implementing the price setting provisions of the Inflation Reduction Act

Media

Featured
Our Defining Edge: Improving Affordability
Our Defining Edge: Improving Affordability
Our Defining Edge: Protecting Innovation
Our Defining Edge: Protecting Innovation
Our Defining Edge: Activating the Ecosystem
Our Defining Edge: Activating the Ecosystem
National Kidney Month: The Value of Innovation
National Kidney Month: The Value of Innovation
National Kidney Month: The Human Cost of Insurance Barriers
National Kidney Month: The Human Cost of Insurance Barriers
Kidney Month is my Kidney-versary: Why Innovation Matters
Kidney Month is my Kidney-versary: Why Innovation Matters
Meet NPLB’s New Executive Director
Meet NPLB’s New Executive Director
8 Ways to Modernize the FDA
8 Ways to Modernize the FDA
Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies
Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies
The Evidence Base: New framework proposed for valuing medicines’ broader societal impact
The Evidence Base: New framework proposed for valuing medicines’ broader societal impact
R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought
R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought
USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.
USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
Cambridge Day: Health care costs keep rising, but biopharma is not the enemy
AI can make it easier to discover new medicines – but Congress is making it harder
AI can make it easier to discover new medicines – but Congress is making it harder

Community Quest

Featured
The Quest to Cure Muscular Dystrophy
The Quest to Cure Muscular Dystrophy
The Quest to Treat Mental Health
The Quest to Treat Mental Health
The Quest to Defeat Lymphoma
The Quest to Defeat Lymphoma
The Quest to Beat Dementia
The Quest to Beat Dementia
The Quest to Treat Blindness
The Quest to Treat Blindness
The Quest to Cure Alzheimer’s
The Quest to Cure Alzheimer’s
The Quest to Defeat Pancreatic Cancer
The Quest to Defeat Pancreatic Cancer
The Quest to Cure Wet AMD
The Quest to Cure Wet AMD
The Quest to Defeat Myositis
The Quest to Defeat Myositis
The Quest to Cure Leukemia
The Quest to Cure Leukemia
The Quest to Beat Epilepsy
The Quest to Beat Epilepsy
The Quest to Treat Autoimmune Nephropathy
The Quest to Treat Autoimmune Nephropathy
The Quest to Beat Lung Cancer
The Quest to Beat Lung Cancer
The Quest to Combat Liver Disease
The Quest to Combat Liver Disease

Op-eds and blog posts

Community Outreach

Press Releases

Featured
Statement from No Patient Left Behind on Upcoming Senate HELP Hearing on Drug Pricing
No Patient Left Behind Welcomes Priscilla VanderVeer as Executive Director
New Analysis Reveals Health Exchange Plans Have Shifted Costs to Sicker Patients
New Analysis Reveals Foreign Countries’ Flawed Value Assessments Undervalue Innovative Medicines by up to 94%
New Study Highlights Challenges in Medicare Part D Treatment Access and Major Concerns over Inflation Reduction Act
New Study Reveals Widespread Concern over Prescription Price Controls, Costs, and Access
NPLB Statement on Murder of Brian Thompson
New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
Getting the Math Right: The Growing Movement to Improve How Medicines Are Valued Will Take Center Stage at ISPOR 2024
APRIL FOOLS’: FTC Announces Zero Copay Mandate
Investors and Innovators Representing more than $309B in Biotech Assets and 624 New Drugs in Development Urge the Congressional Budget Office to Update its Drug R&D Policy Impact Model
Statement / Background Info Regarding the Institute for Clinical and Economic Review’s (ICER) Proposed Value Assessment Framework
Innovative Medicines Provide Greater Value to Patients and Society than Previously Calculated
NPLB Statement on ICER’s Flawed Value Assessment Framework

We’re building support across the biotech ecosystem

BECOME A FIRST RESPONDER & THOUGHT PARTNER

Sign up to receive action alerts. Help protect access to lifesaving medicines & preserve innovation for those still waiting for a cure.

Sign Up
Sign Up